The Place of Phosphodiesterase Inhibitors

  • J. L. Vincent
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 6)


Myocardial contractility can be increased by various mechanisms other than those exerted by digitalis or adrenergic agents. The so-called non-digitalis, nonadrenergic agents actually encompass a wide variety of substances among which drugs supposed to act by inhibition of the myocardial phosphodiesterase (type III) appear most promising. Phosphodiesterase (PDE) inhibitors act to increase intracellular cyclic adenosine monophosphate (AMP) concentration.


Acute Heart Failure Myocardial Contractility Severe Heart Failure Severe Congestive Heart Failure Adrenergic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Benotti JR, Grossman W, Braunwald E, Davolos DD, Alousi AA (1978) Hemodynamic assessment of amrinone: A new inotropic agent. N Engl J Med 299: 1373–1377PubMedCrossRefGoogle Scholar
  2. 2.
    Ansell J, Tiarks C, McCue J, Parrilla N, Benotti JR (1984) Amrinone-induced thrombocytopenia. Arch Intern Med 14: 949–952CrossRefGoogle Scholar
  3. 3.
    Hines R, Barash PG (1987) Amrinone associated thrombocytopenia: Does it occur with short term administration? Anesthesiology 67: A599 (Abstract)CrossRefGoogle Scholar
  4. 4.
    Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS (1984) Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure: Dose-response relationships and comparison to nitroprusside. J Clin Invest 75: 643–649CrossRefGoogle Scholar
  5. 5.
    Biddle TL, Benotti JR, Creager MA, et al (1987) Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol 59: 1345–1350PubMedCrossRefGoogle Scholar
  6. 6.
    Vincent JL, Goldstein J, Leeman M, Lheureux P, Kahn RI (1984) Administration of sulmazol in low-output states following cardiac surgery. Chest 86: 602–606PubMedCrossRefGoogle Scholar
  7. 7.
    Herzig NW, Feile K, Rüegg JC (1981) Activating effects of ARL 115 BS on the Ca’ sensitive force, stiffness and unloaded shortening velocity ( V max) in isolated contractile structures from mammalian heart muscle. Arzneim Forsch/Drug Res 31: 189–191Google Scholar
  8. 8.
    Amin DK, Shah PK, Hulse S, Shellock FG, Swan HJC (1984) Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure. Am Heart J 108: 1285–1292PubMedCrossRefGoogle Scholar
  9. 9.
    Crawford MH, Richards KL, Sodums MT, Kennedy GT (1984) Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance. Am J Cardiol 53: 1051–1053PubMedCrossRefGoogle Scholar
  10. 10.
    Massie BM, Cornyn J, Topic N, Loge D, Podolin RA (1987) Combined hemodynamic and scintigraphic assessment of piroximone (MDL 19,205) and comparison with dobutamine and nitroprusside. Am J Cardiol 60: 647–653PubMedCrossRefGoogle Scholar
  11. 11.
    Weber KT, Janicki JS, Jain MC (1986) Proximone (MDL 19,205) in the treatment of unstable and stable chronic cardiac failure. Am Heart J 114: 805–813CrossRefGoogle Scholar
  12. 12.
    Axelrod RJ, De Marco T, Dae M, Botvinick EH, Chatterjee K (1987) Hemodynamic and clinical evaluation of proximone, a new inotrope-vasodilator agent, in severe congestive heart failure. J Am Coll Cardiol 9: 1124–1130PubMedCrossRefGoogle Scholar
  13. 13.
    Jafri SM, Burlew BS, Goldberg AD, Olson S, Froelich JW, Goldstein S (1987) Hemodynamic, pharmacokinetic and clinical response to CI-930 in congestive heart failure due to ischemic or dilated cardiomyopathy. Am J Cardiol 59: 1126–1130PubMedCrossRefGoogle Scholar
  14. 14.
    Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR (1987) Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res 61: 539–547PubMedGoogle Scholar
  15. 15.
    Wilmshurst PT, Thompson DS, Juul SM, Jenkins BS, Coltart DJ, Webb-Peploe MM (1984) Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. Br Heart J 52: 38–48PubMedCrossRefGoogle Scholar
  16. 16.
    Ludmer PL, Wright RF, Arnold JMO, Ganz P, Braunwald E, Colucci WS (1986) Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation 73: 130–137PubMedCrossRefGoogle Scholar
  17. 17.
    Herrmann HC, Ruddy TD, Dec GW, Strauss HW, Boucher CA, Fifer MA (1987) Inotropic effect of enoximone in patients with severe heart failure: Demonstration by left ventricular end-systolic pressure-volume analysis. J Am Coll Cardiol 9: 1117–1123PubMedCrossRefGoogle Scholar
  18. 18.
    Grayson RF, Marino PN, Yaster M, Weiss JL, Kass DA (1987) Is amrinone an inotrope in vivo? Assessment by end-systolic pressure-volume relationships. Anesthesiology 67: A600 (Abstract)CrossRefGoogle Scholar
  19. 19.
    Miller WP, Vander Ark CR, Wiederholt P (1987) Effect of oral milrinone on end-systolic relations in patients with severe congestive heart failure. Am J Cardiol 60: 842–846PubMedCrossRefGoogle Scholar
  20. 20.
    Arnold JMO, Ludmer PL, Wright RF, Ganz P, Braunwald E, Colucci WS (1986) Role of reflex sympathetic withdrawal in the hemodynamic response to an increased inotropic state in patients with severe heart failure. J Am Coll Cardiol 8: 413–418PubMedCrossRefGoogle Scholar
  21. 21.
    Anderson JL, Bairn DS, Fain SA, et al (1987) Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: A multicenter study. J Am Coll Cardiol 9: 711–722PubMedCrossRefGoogle Scholar
  22. 22.
    Goldstein RA, Geraci SA, Gray EL, Rinkenberger RL, Dougherty AH, Naccarelli GV (1986) Electrophysiologic effects of milrinone in patients with congestive heart failure. Am J Cardiol 57: 624–628PubMedCrossRefGoogle Scholar
  23. 23.
    Holmes JR, Kubo SH, Cody RI, Kligfield P (1985) Milrinone in congestive heart failure: Observations on ambulatory ventricular arrhythmias. Am Heart J 110: 800–806PubMedCrossRefGoogle Scholar
  24. 24.
    Monrad ES, McKay RG, Baim DS, et al (1984) Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 70: 1030–1037PubMedCrossRefGoogle Scholar
  25. 25.
    Piscione F, Jaski BE, Wenting GJ, Serruys PW (1987) Effect of a single oral dose of milrinone on left ventricular diastolic performance in the failing human heart. J Am Coll Cardiol 10: 1294–1302PubMedCrossRefGoogle Scholar
  26. 26.
    Kereiakes DJ, Viquerat C, Lanzer P, et al (1984) Mechanisms of improved left ventricular function following intravenous MDL-17,043 in patients with severe chronic heart failure. Am Heart J 108: 1278–1284PubMedCrossRefGoogle Scholar
  27. 27.
    Campbell CA, Reddy BR, Alker KJ, Wynne J, Kloner RA (1987) Effect of milrinone on acute myocardial infarct size. Am J Cardiol 60: 422–423PubMedCrossRefGoogle Scholar
  28. 28.
    Kabela E, Barcenas L, Farah A (1986) The effects of milrinone (Win 47203) on the coronary blood flow and oxygen consumption of the dog heart lung preparation. Am Heart J 111: 702–708PubMedCrossRefGoogle Scholar
  29. 29.
    Monrad ES, Bairn DS, Smith HS, Lanoue A, Braunwald E, Grossman W (1985) Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. Circulation 71: 972–979PubMedCrossRefGoogle Scholar
  30. 30.
    Grose R, Strain J, Greenberg M, LeJemtel TH (1986) Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. J Am Coll Cardiol 7: 1107–1113PubMedCrossRefGoogle Scholar
  31. 31.
    Rossing TH, Shannon K, Miller MJ (1987) Effects of milrinone on contractility of the rat diaphragm in vitro. Am Rev Respir Dis 136: 841–844PubMedCrossRefGoogle Scholar
  32. 32.
    Leeman M, Lejeune P, Melot C, Naeije R (1987) Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD. Chest 91: 662–666PubMedCrossRefGoogle Scholar
  33. 33.
    Konstam MA, Cohen SR, Weiland DS, et al (1986) Relative contribution of inotropic and vasodilator effects to amrinone-induced hemodynamic improvement in congestive heart failure. Am J Cardiol 57: 242–248PubMedCrossRefGoogle Scholar
  34. 34.
    Makela VHM, Kapur PA (1987) Comparison of milrinone with amrinone or nitroprusside during enflurane anesthesia in the dog. Am J Cardiol 57: 242–248Google Scholar
  35. 35.
    Amin DK, Shah PK, Hulse S, Shellock F (1985) Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure. Am Heart J 109: 1006–1012PubMedCrossRefGoogle Scholar
  36. 36.
    Likoff MJ, Ulrich S, Hakki AH, Iskandrian AS (1986) Comparison of acute hemodynamic response to dobutamine and intravenous MDL-17,043 (enoximone) in severe congestive heart failure secondary to ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 57: 1328–1334PubMedCrossRefGoogle Scholar
  37. 37.
    Amin DK, Shah PK, Shellock FG, et al (1985) Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure. Am Heart J 109: 91–98PubMedCrossRefGoogle Scholar
  38. 38.
    Uretsky BF, Generalovich T, Verbalis JG, Valdes AM, Reddy PS (1986) Comparative hemodynamic and hormonal response of enoximone and dobutamine in severe congestive heart failure. Am J Cardiol 58: 110–116PubMedCrossRefGoogle Scholar
  39. 39.
    Gage J, Rutman H, Lucido D, LeJemtel TH (1986) Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 74: 367–373PubMedCrossRefGoogle Scholar
  40. 40.
    Guimond JG, Matuschak GM, Meyers F, Keating D (1986) Augmentation of cardiac function in end-stage heart failure by combined use of dobutamine and amrinone. Chest 90: 302–304PubMedCrossRefGoogle Scholar
  41. 41.
    Uretsky BF, Lawless CE, Verbalis JG, Valdes AM, Kolesar JA, Reddy PS (1987) Combined therapy with dobutamine and amrinone in severe heart failure: Improved hemodynamics and increase activation of the renin-angiotensin system with combined intravenous therapy. Chest 92: 657–662PubMedCrossRefGoogle Scholar
  42. 42.
    LeJemtel TH, Maskin CS, Mancini D, Sinoway L, Feld H, Chadwick B (1985) Systemic and regional hemodynamic effects of captopril and mirinone administered alone and concomitantly in patients with heart failure. Circulation 72: 364–369PubMedCrossRefGoogle Scholar
  43. 43.
    Feldman MD, Copelas L, Gwathmey JK, et al (1987) Deficient production of cyclic AMP: Pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75: 331–339PubMedCrossRefGoogle Scholar
  44. 44.
    Vincent JL, Madhoun P, Primo G, Kahn RI (1989) Potentiation of the effects of enoximone by a dobutamine infusion (submitted)Google Scholar
  45. 45.
    Vincent JL, Carlier E, Berré J, et al (1988) Administration of enoximone in cardiogenic shock. Am J Cardiol (in press)Google Scholar
  46. 46.
    Vincent JL, Van Reeth O, Van Gogaert E, Berré J, Kahn RI (1986) Use of the new inotropic agent ARL-115 BS to treat severe myocardial depression in septic shock. Crit Care Med 14: 661–662CrossRefGoogle Scholar
  47. 47.
    Vincent JL, Domb M, Van der Linden P, et al (1988) Amrinone administration in endotoxic shock. Circ Shock 25: 75–83PubMedGoogle Scholar
  48. 48.
    Vincent JL, de Boelpaepe C, Luypaert P, Contempré B, Schwartz D, Coussaert E (1988) Association of amrinone with norepinephrine in endotoxic shock in dogs: An experimental study. Crit Care Med 16 (4): 402 (Abstract)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • J. L. Vincent

There are no affiliations available

Personalised recommendations